Novartis India Limited.

BSE: NOVARTIND500672ISIN INE234A01025

Healthcare
Pharmaceuticals
BSE 1000

BSE listing

Share price

₹2,057.50-23.35 (-1.12%)

as of 18 Sep 2026

52W high: ₹2,588.00
52W low: ₹750.00
Off 52W high: -20.50%
1M return: +34.34%
3M return: +48.19%
6M return: +120.24%
1Y return: +128.53%
20D avg volume: 22,848
50 DMA: ₹1,674.41
200 DMA: ₹1,182.37

Key ratios Standalone

Market cap: ₹5,080 Cr
Current price: ₹2,057.50
52W high / low: ₹2,588.00 / ₹750.00
Face value: ₹5.00
P/E: 51.96
P/B: 6.97
EPS (TTM): ₹39.60
Book value / share: ₹295.19
ROE: 13.41%
ROCE: 15.70%
Operating margin: 42.05%
Net margin: 31.03%
Debt / equity: 0.00
Net debt: ₹-52.50 Cr
Interest cover: 103.90
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 36.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	103.81	90.55	85.90	90.33	87.55	83.88	—
	8.74	10.01	8.75	9.40	10.61	10.63	—
	69.38	70.42	65.00	67.08	60.94	60.62	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	76.05	68.34	40.77	54.08	47.39	64.84	—
	4.72	4.35	6.14	5.30	5.29	3.17	—
	0.06	0.07	0.98	0.11	0.10	0.12	—
	0.42	0.42	0.48	0.52	0.53	0.53	—
	8.51	13.40	8.50	10.63	8.25	7.50	—
	43.17	30.14	29.65	32.65	37.22	33.89	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	43.17	30.14	29.65	32.65	37.22	33.89	—
	10.96	4.89	13.56	8.43	9.60	4.59	—
	32.21	25.25	16.09	24.22	27.62	29.30	—
	13.05	10.23	6.52	9.81	11.19	11.87	—
Key metrics
	43.65	30.63	31.11	33.28	37.85	34.54	—
	42.00%	33.80%	36.20%	36.80%	43.20%	41.20%	—
	31.00%	27.90%	18.70%	26.80%	31.50%	34.90%	—
	—	3.60%	—	4.10%	—	4.20%	—
	18.60%	8.00%	—	—	—	—	—
	16.60%	-13.80%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	370.59	354.33	356.27	—
	36.90	38.77	41.96	—
	271.88	263.44	267.81	—
	0.00	0.00	0.00	—
	239.24	210.58	199.07	—
	20.51	21.08	18.72	—
	1.22	1.26	0.77	—
	1.84	1.95	2.19	—
	41.04	40.78	43.31	—
	135.61	129.66	130.42	—
	0.00	0.00	0.00	—
	135.61	129.66	130.42	—
	37.84	36.48	29.52	—
	97.77	93.18	100.90	—
	39.61	37.74	40.87	—
Key metrics
	138.67	132.87	133.38	—
	37.42%	37.50%	37.40%	—
	26.38%	26.30%	28.30%	—
	—	15.70%	16.30%	—
	—	-0.50%	—	—
	—	-7.70%	—	—
	—	46.39	74.57	—
	—	0.50	0.74	—
	—	0.00	0.00	—
	—	-52.50	-52.07	—
	—	36.8	30.5	—
Balance sheet
	—	978.27	947.81	—
	—	768.25	745.82	—
	—	52.50	52.07	—
	—	37.05	40.14	—
	—	53.32	41.11	—
	—	9.53	15.60	—
	—	2.88	4.54	—
	—	54.65	51.47	—
	—	144.97	142.05	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	817.83	784.96	—
Cash flow
	—	46.73	74.57	—
	—	17.63	-3.31	—
	—	-63.93	-64.15	—
	—	0.34	0.00	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 70.68%

Holder	Type	Holding	Previous	Change
Waverise Investments Limited	Promoter	56.45%	—	—
Chryscapital Fund X	Promoter	10.32%	—	—
Two Infinity Partners	Promoter Group	3.91%	—	—
Atul Limited	Public	1.52%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Corrigendum to the Notice of 78th Annual General Meeting dated August 27, 202618 Sep 2026 · AGM/EGM / AGM
Transcript of the Analysts / Institutional Investors Call held on September 11, 2026.15 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of the Audio Recording of the Investor / Analyst Call held on Friday, September 11, 2026.12 Sep 2026 · Company Update / Analyst / Investor Meet
With reference to the intimation of the Investor / Analyst Call dated September 08, 2026, please find attached herewith the Investor Presentation in relation to the same.11 Sep 2026 · Company Update / Investor Presentation
Intimation pursuant to Regulation 36(1)(b) of the SEBI LODR Regulations to non-email shareholders regarding the Weblink and Annual Report for FY 2025-26 by the way of physical dispatch of letters.9 Sep 2026 · Company Update / General
Intimation regarding the Investor / Analyst Call scheduled to be held on Friday, September 11, 2026, 04:00 PM IST onwards, through Physical and Virtual Mode.8 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising ....8 Sep 2026 · Company Update / General
Intimation regarding the acquisition of trademarks "Minipress" and "Minipres" registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products ....7 Sep 2026 · Company Update / General
Newspaper Publication made on September 03, 2026, in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02, 2026, regarding the Notice of the 78th ....3 Sep 2026 · Company Update / Newspaper Publication
Annual Report of Novartis India Limited for FY 2025-262 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 78th Annual General Meeting of Novartis India Limited to be held on Thursday, September 24, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM)2 Sep 2026 · AGM/EGM / AGM
BRSR Report of Novartis India Limited for FY 2025-262 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
The Intimation is submitted with BSE regarding the information provided to the Members of the Company for the 78th Annual General Meeting through Newspaper Advertisement28 Aug 2026 · Company Update / Newspaper Publication
Outcome of the meeting of the Board of Directors of the Company held on August 17, 202617 Aug 2026 · Others / Outcome without intimation
Intimation of the outcome of the Board Meeting held today i.e. August 07, 20267 Aug 2026 · Others / Outcome without intimation
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Press Release.29 Jul 2026 · Company Update / Press Release / Media Release
Outcome of the 247th meeting of the Board of Directors held today, i.e, Wednesday, July 29, 2026.29 Jul 2026 · Company Update / General
Outcome of the 246th Board Meeting of the Board of Directors of Novartis India Limited held today i.e, Wednesday, July 29, 2026.29 Jul 2026 · Company Update / General
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July 29, 2026 took note of the Resignation of Mr. Christopher David Snook as ....29 Jul 2026 · Company Update / Resignation of Chairman
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July 29, 2026 took note of the Resignation of the Directors of the company.29 Jul 2026 · Company Update / Resignation of Director
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July, 26, 2026 took note of resignation of Ms. Shilpa Joshi as the Chief Financial ....29 Jul 2026 · Company Update / Resignation of Chief Financial Officer (CFO)
The Board of Directors of Novartis India Limited ("the Company'') in its meeting today, July 29, 2026 approved the Change in Control of the Company.29 Jul 2026 · Company Update / General
The Board of Directors of Novartis India Limited ("the Company") at its Meeting held today, July 29, 2026 approved the Cessation of the exisiting Directors.29 Jul 2026 · Company Update / Cessation
The Board of Directors of Novartis India Limited ("the Company") held today, i.e, Wednesday, July 29, 2026 approved the Appointment and Resignation of Directors.29 Jul 2026 · Company Update / Change in Management
Disclosure in terms of Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations, 2015.29 Jul 2026 · Company Update / General
Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 201529 Jul 2026 · Company Update / General
Intimation under Regulation 31A (10) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").29 Jul 2026 · Company Update / General
Outcome of the 245th Meeting of the Board of Directors of Novartis India Limited ("the Company") held today, Wednesday, July 29, 2026.29 Jul 2026 · Others / Outcome without intimation
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for WaveRise Investments Ltd29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Intimation of Newspaper Advertisement by Novartis India Limited ("the Company") regarding the publication of Unaudited Financial Results of the Company for the Quarter ended June 30, 2026.24 Jul 2026 · Company Update / Newspaper Publication
Financial Results along with the Limited Review Report of Novartis India Limited for the quarter ended June 30, 2026.23 Jul 2026 · Result / Financial Results
Outcome of the meeting of the Board of Directors of Novartis India Limited held on Thursday, July, 23, 2026.23 Jul 2026 · Board Meeting / Outcome of Board Meeting
Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, issued to Novartis India Limited ("The Company") ....13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of India ....10 Jul 2026 · Company Update / General
Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....7 Jul 2026 · Board Meeting / Board Meeting
Intimation of the Closure of the Trading Window for Novartis India Limited ("the Company") for the quarter ended June 30, 2026.30 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....25 Jun 2026 · Company Update / Open Offer
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the captioned Open Offer to the Public Shareholder ....23 Jun 2026 · Company Update / Open Offer
Axis Capital Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Disclosure of number of Equity Shares tendered in connection with the Open Offer to the Public Shareholder ....23 Jun 2026 · Company Update / Open Offer
Axis Capital Ltd ("Manager to the Open Offer") has informed BSE regarding Updates on Open offer for acquisition of up to 64,19,608 (sixty four lakhs nineteen thousand six hundred and eight) ....19 Jun 2026 · Company Update / Open Offer

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 25.0000	23 Jul 2025	23 Jul 2025	—
Final Dividend - Rs. - 25.0000	23 Jul 2024	—	—

Board meetings

23 Jul 2026 Board Meeting - Financial Results